Pfizer Animal Health has announced that the therapy PIRSUE® has received approval for extended treatment. Be sure to ask your veterinarian for more information.
Dairy producers can now use PIRSUE® (pirlimycin hydrochloride) Sterile Solution for extended duration therapy treatment of subclinical and clinical mastitis. Pfizer Animal Health recently received the supplemental approval for PIRSUE, which is indicated for the treatment of both clinical and subclinical mastitis in lactating dairy cattle. PIRSUE is labeled for intramammary infections associated with Staphylococcus species such as Staphylococcus aureus and Streptococcus species such asStreptococcus agalactiae, Streptococcus dysgalactiae and Streptococcus uberis.
“This new approval allows your vet to prescribe PIRSUE once daily for up to eight consecutive days,” said Austin Belschner, DVM, Director, Pfizer Dairy Veterinary Operations. “This provides true flexibility in designing treatment protocols for a wide variety of Gram-positive mastitis pathogens on your dairy.”
“By using extended therapy treatment on mastitis cases, you’re more likely to obtain a bacteriological cure and thus lower the risk of re-treating the animal,” said Belschner.